General Information of the Drug (ID: M6APDG02839)
Name
(E)-N-(4-Phenylthiazol-2-yl) cinnamamide
Synonyms
CHEMBL452100; 2-Cinnamamido-4-phenylthiazole; (2E)-3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)prop-2-enamide; 1107621-03-3; AC1LEPJR; (E)-N-(4-Phenylthiazol-2-yl) cinnamamide; ZINC60264; WOJRHCOBUKJCAJ-VAWYXSNFSA-N; MolPort-019-760-060; MolPort-001-931-977; HMS1397P15; STK173781; BDBM50255301; N-(4-phenylthiazol-2-yl)cinnamamide; AKOS000523355; MCULE-8934603681; BAS 00417267; ST4016450; 3-Phenyl-N-(4-phenyl-thiazol-2-yl)-acrylamide; AG-690/11629440; 3-phenyl-N-(4-phenyl-1,3-thiazol-2-yl)acrylamide; F0298-0058; A0793/0037152
    Click to Show/Hide
Status
Investigative
Structure
Formula
C18H14N2OS
InChI
1S/C18H14N2OS/c21-17(12-11-14-7-3-1-4-8-14)20-18-19-16(13-22-18)15-9-5-2-6-10-15/h1-13H,(H,19,20,21)/b12-11+
InChIKey
WOJRHCOBUKJCAJ-VAWYXSNFSA-N
PubChem CID
690181
TTD Drug ID
D04ZQJ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Poly [ADP-ribose] polymerase 1 (PARP1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for (E)-N-(4-Phenylthiazol-2-yl) cinnamamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-N-(4-Phenylthiazol-2-yl) cinnamamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for (E)-N-(4-Phenylthiazol-2-yl) cinnamamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of (E)-N-(4-Phenylthiazol-2-yl) cinnamamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
References
Ref 1 METTL3 promotes oxaliplatin resistance of gastric cancer CD133+?stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci. 2022 Feb 18;79(3):135. doi: 10.1007/s00018-022-04129-0.
Ref 2 Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. doi: 10.1021/jm800902t.